Arch Nears First Clinical Trial of AB569 as Treatment for Antibiotic-Resistant Lung Bacteria
Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria that infect the lungs of those with cystic fibrosis (CF) and other pulmonary conditions. The Phase 1 clinical trial, to be conducted at the Cincinnati Veterans Affairs Medical Center (CVAMC),…